Lumiracoxib

罗美昔布

Report date: 2023/03/21 16:11:55
NME

Base Information

Drug NameLumiracoxib
Drug Alias Namelumiracoxibum鲁米昔布芦米昔布鲁米考昔氯美昔布 +[10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclooxygenase-2 inhibitors
TargetsCyclooxygenase-2
Therapy Area/IndicationsAcute PainDysmenorrheaOsteoarthritis, Knee +[7
Global Approved IndicationsAcute PainDysmenorrheaOsteoarthritis +[4
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMexico
Original Approved Date2003/05/03
Country/TerritoryCzechiaCanadaUnited States +[22
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesNovartis Pharma Ag
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNovartis Pharma Ag
Active IndicationsAcute PainDysmenorrheaOsteoarthritis +[4
Inactive IndicationsOsteoarthritis, KneeOsteoarthritis, HipArthritis

Other Information

ATC CodeM01AH06